Global Alzheimer’s Platform Foundation Praises the FDA Approval of the IV Maintenance Dosing for the Treatment LEQEMBI
Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]